BA

Barricade Therapeutics

Fort Worth, US · Delaware corporation · 1 known investors

barricadetherapeutics.com ↗

Barricade Therapeutics is a clinical-stage oncology company developing BT-1501, an investigational once-daily oral small-molecule EBP inhibitor built on its TASIN platform to target genetic drivers of colorectal cancer. The therapy is aimed at patients with advanced and metastatic colorectal cancer and is advancing toward IND submission and first-in-human clinical trials.

Investors · 1

GR

Green Park & Golf VenturesDallas · $500K – $2M

Competitors · 5

by search overlap

CY

Cybrexa, Inc.4 shared keywordsCybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.

PA

Parabilis Medicines4 shared keywordsHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.

DI

Dialectic Therapeutics4 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.

BI

Bicycle4 shared keywordsBicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.

OB

Obsidiantx3 shared keywordsObsidian Therapeutics develops engineered cell and gene therapies, including its lead candidate OBX-115 in advanced melanoma. Its proprietary cytoDRiVE platform uses drug responsive domains (DRDs) to control protein function via an FDA-approved small molecule.

Companies competing with Barricade Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.